Trial Profile

A randomized controlled clinical trial of neoadjuvant pembrolizumab in patients with recurrent glioblastoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Glioblastoma
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

26 Feb 2019 New trial record
19 Feb 2019 According to a Dana-Farber Cancer Institute media release, this study was carried out by scientists from Dana-Farber Cancer Institute and the University of California at Los Angeles (UCLA).
19 Feb 2019 Results presented in a Dana-Farber Cancer Institute media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com